Hanmi Pharm has recently won the approval for its hypertension- hyperlipidemia three-compound complex Amosartan Q (compound: amlodipine +losartan+rosuvastatin), completing the “Amosartan family.”
Hanmi한미약품 said Tuesday that it would raise the Amosartan family -- Amosartan, Amosartan Plus, and Amosartan Q – to a blockbuster with 100 billion won ($89 million) in annual sales.
Amosartan tops Hanmi’s sales list, with the annual turnover of 67 billion won. It is a hypertension treatment complex to combine ARB series’ hypertension treatment compounds of losartan and the CCB series’ compound amlodipine.
MSD is exporting Amosartan to about 50 countries with the brand name of CozeXQ. This is the example of incrementally modified drug developed by Korean pharmaceutical company and sold to overseas markets in collaboration with a multinational drugmaker.
The drug has received initial therapy indication for stage-2 hypertension patients for the first time among hypertension complex and can be provided to hypertension patients with median severity or more at an early stage of treatment.
Hanmi released Amosartan Plus as the follow-up drug of Amosartan with diuretic compound Chlortalidon. Amosartan is more effective for patients who can’t reduce blood pressure with drugs that have two compounds.
Lessening the risk of cardiovascular diseases is important for hypertension patients. In the large-scale research ALLHAT, researchers proved Chlortalidon lowers blood pressure by reducing blood stream and prevents cardiovascular diseases.
Amosartan Q is hypertension and hyperlipidemia complex with three compounds to combine Amosartan and hyperlipidemia compound rosuvastatin.
In the clinical trials conducted by Professor Park Seung-woo 박승우 of School of Medicine of Sungkyunkwan University for 143 patients with hypertension and dyslipidemia, patients who took Amosartan Q showed 48 percent less LDL-C and 12.6mmHg lower systolic blood pressure than the patients who took a single hypertension drug during eight weeks of the treatment.
High treatment effect is expected because of easy usage and well-controlled hypertension and hyperlipidemia with one dose a day.
Hanmi will release Amosartan in the second half of this year.
And Hanmi will focus on increasing the combined sales of Amosartan, Amosartan Plus, and Amosartan Q to 100 billion won annually. Based on data accumulated in the clinical field and through various researches, Hanmi plans to develop it as a blockbuster drug by focusing on marketing.
“Amosartan is a prescribed drug whose efficacy to reduce blood pressure has already been proved through abundant clinical data,” said Park Myung-hee, managing director of marketing at Hanmi. “We will concentrate on raising the family’s sales to 100 billion won.”